SCHEMBL6980930

SCHEMBL6980930

CC(C)CC(NC(=O)OC(C)(C)C)C(=O)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.59
MC4R P32245 4/20 0.56
ALDH1A1 P00352 4/20 0.54
LMNA P02545 1/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 1/20 0.53
HRH2 P25021 3/20 0.51
HRH1 P35367 3/20 0.51
TGM2 P21980 2/20 0.47
TGM6 O95932 1/20 0.47
F13A1 P00488 1/20 0.47
TGM1 P22735 1/20 0.47
KDM4E B2RXH2 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CCR1 P32246 1/20 0.46
DRD2 P14416 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6986093 0.88 MAPK1 (0.56) MAPK1MC4RALDH1A1LMNAKMT2A
SCHEMBL6982783 0.87 MAPK1 (0.61) MAPK1MC4RALDH1A1LMNAKMT2A
SCHEMBL6982596 0.85 SMN1; SMN2 (0.54) MAPK1MC4RALDH1A1LMNAKMT2A
SCHEMBL6976074 0.85 MAPK1 (0.52) MAPK1MC4RALDH1A1LMNAKMT2A
SCHEMBL6985692 0.84 CCR1 (0.51) MC4RALDH1A1LMNAKMT2AMEN1
SCHEMBL6985689 0.84 CCR1 (0.51) MC4RALDH1A1LMNAKMT2AMEN1
SCHEMBL6981597 0.81 MAPK1 (0.52) MAPK1ALDH1A1LMNAKMT2AMEN1
SCHEMBL6985297 0.80 ALDH1A1 (0.65) MAPK1ALDH1A1LMNAKMT2AMEN1
SCHEMBL4974155 0.80 MAPK1 (0.64) MAPK1ALDH1A1LMNAKMT2AMEN1
SCHEMBL1706172 0.79 MAPK1 (0.55) MAPK1ALDH1A1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
US-5935959-A CYSTEINE PROTEASE INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
CN-1163145-A Inhibiting agent for vascular formation SENJI SEIYAKU K K (JP) 1997-10-29 CN disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed